BACKGROUND/OBJECTIVES:Southeastern Europe and Croatia have served as a genetic crossroads between the Near East and Europe since prehistoric times, shaped by numerous and repeated migrations. By integrating 19 newly generated ancient genomes with 285 previously published ancient genomes from Croatia, we investigated patterns of maternal and paternal landscapes from the Neolithic, Bronze, and Iron Ages through to the Antiquity and medieval periods, as well as the modern Croatian population. METHODS:Ancient DNA extraction from human remains and library preparation were conducted in dedicated clean-room facilities, followed by high-throughput sequencing on the Illumina platform. Sequencing data were analyzed with established pipelines to determine mitochondrial and Y-chromosomal haplogroups and the genetic sex of individuals. RESULTS:New ancient data reveal a predominantly European maternal profile, dominated by haplogroups H, U, and HV0, whereas Y-chromosomal lineages are characterized by J subclades and R1a, with limited representation of R1b and the absence of I2a. When combined with published ancient Croatian genomes, the results reveal similar haplogroup diversity and patterns, as well as the expansion of mtDNA haplogroup H over time and a substantial increase in Y-chromosome R1a and I2a haplogroup frequency from the prehistoric to the modern period. CONCLUSIONS:Although the analyzed samples are heterogeneous and originate from different historical periods, their genetic signatures conform to the broader patterns expected for the region. In a wider context, the ancient Croatian mitochondrial data reveal stronger genetic persistence from prehistory to modern times, unlike paternal lineages, which show significantly higher divergence.
X-linked hypophosphatemia (XLH) is the most common form of inherited rickets, resulting in short stature despite treatment with oral phosphate and active vitamin D. Detailed data of anthropometric parameters at birth, during infancy, and on the influence of an affected parent on outcome are lacking. In this prospective multicenter observational study, conducted from 1998 to 2023 in Germany, Austria, and Switzerland, body length, body weight, and head circumference were investigated in 198 children with XLH from birth until the age of 18 years, all being only on supplementation therapy. XLH newborns presented with disproportionate body shape characterized by decreased birth length relative to weight and head circumference with a 2.4-fold increased risk to be born small for gestational age (SGA). A positive family history for XLH was associated with lower anthropometric characteristics at birth. Body disproportion increased during 0–2 years old, resulting in significantly increased head circumference (+ 0.82 SD) and reduced body length (−2.00 SD) compared to healthy 2-year-old patients. Supplementation therapy failed to prevent progressive growth failure and reduced final height, regardless of whether treatment was started early due to an affected family member, which was associated with overall poor control of metabolic bone disease indicated by persistent hypophosphatemia and rising alkaline phosphatase z-score. XLH is associated with an increased risk for SGA and progressive disproportional body growth during infancy. Routine medical check-ups may soon use this unique growth pattern to identify children with XLH. Supplemental therapy fails to prevent progressive growth failure.
A series of novel 2-phenylbenzothiazole-appended acylthiourea (AcTU) ligands and their Ru(II) half-sandwich complexes was synthesized and fully characterized using 1H and 13C NMR, IR spectroscopy, elemental analysis and single-crystal X-ray diffraction. Crystal structures were determined for [dichloro(p-cymene)ruthenium (II) complexes 4gRu, 5eRu, and 5fRu, that adopt "piano-stool" geometry, with the eta 6-arene ligand as a seat, AcTU and two chlorides as the three legs in the pseudo-octahedral crystal field. The synthesized compounds were evaluated against lung (H460), colorectal (SW620), hepatocellular (HepG2), and breast (MCF-7) cancer cell lines, as well as non-tumorigenic HEK293 cells, and compared to cisplatin, a platinum-based chemotherapy drug. The 4-fluorobenzoyl-substituted ligand 5c and the Ru(II) complexes 4cRu and 5cRu demonstrated the highest potency and selectivity, particularly in MCF-7 cells, outperforming anti-proliferative activity of cisplatin in MCF7 cells while maintaining low toxicity toward normal HEK293T cells. Molecular docking and end-point binding free energy calculation studies suggested that 4c and 5c may target the STAT3 SH2 domain, with 4c showing stronger binding stability and 5c offering a broader interaction network, indicating potential advantages in selectivity. In silico ADMET predictions confirmed favorable drug-like properties for the ligands, whereas Ru(II) complexes exhibited reduced bioavailability due to increased size and lipophilicity. Overall, the results demonstrate that the 4-fluorobenzoyl-substituted ligand 5c emerges as the most promising candidate, with superior selectivity and efficacy in breast cancer cells compared with cisplatin, while displaying low cytotoxicity in normal cells, favorable drug-like properties, and a low predicted risk of acute toxicity, thereby identifying it as a potential novel anti-breast cancer agent.
Population genetics and molecular anthropology have undergone remarkable methodological and conceptual development over the past two decades [...]